This CPB on benralizumab (Fasenra) has been revised to: (i) remove a requirement that the prerequisite blood eosinophil level be obtained within 12 weeks of initial dosing; (ii) remove a requirement for 2 or more asthma exacerbations in past 12 months; (iii) remove pre-bronchodilator FEV1 criterion; (iv) add a note on smoking cessation counseling; (v) update dosing recommendations; and (vi) restructure the nomenclature and format of the medical necessity criteria.